1.	Screening Trial to Study Eligibility of Patients to Participate in Head and Neck Surgery Clinical Trials
2.	Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
3.	Peripheral Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia
4.	Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
5.	Biological Therapy in Treating Patients With Metastatic Melanoma
6.	Vaccine Therapy in Treating Patients With Stage II or Stage III Melanoma That Has Been Surgically Removed
7.	Screening Individuals and Families at High Risk for Hematologic Cancers
8.	Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
9.	Study of Individuals and Families at High Risk for Breast or Ovarian Cancer
10.	Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
11.	Erlotinib and Irinotecan in Treating Patients With Advanced Solid Tumors
12.	Study of Individuals and Families at High Risk for Melanoma
13.	Combination Chemotherapy Followed By Observation or Surgery in Treating Patients With Stage II or Stage III Cancer of the Urothelium
14.	Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
15.	EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
16.	Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
17.	Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
18.	Epoetin beta in Treating Anemia in Patients With Cervical Cancer
19.	Radiation Therapy in Preventing CNS Metastases in Patients With Non-Small Cell Lung Cancer
20.	Combination Chemotherapy in Treating Patients With Colon Cancer
21.	Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
22.	Sirolimus in Treating Patients With Glioblastoma Multiforme
23.	Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Mycosis Fungoides/Sezary Syndrome
24.	Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
25.	Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
26.	Combination Chemotherapy in Treating Women With Breast Cancer
27.	Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
28.	Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
29.	Flavopiridol Plus Radiation Therapy Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
30.	Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
31.	Screening Study of Surgery and CA 125 Levels in Participants at Increased Genetic Risk of Ovarian Cancer
32.	Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
33.	Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
34.	EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
35.	Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
36.	Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
37.	Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
38.	Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
39.	Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and Radiation Therapy with Donor Bone Marrow Transplant in Treating Patients with Hematologic Cancer
40.	Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
41.	PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
42.	Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
43.	Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
44.	Cancer Risk in Individuals Who Have a Xeroderma Pigmentosum Gene Alteration Compared With Those Who Don't
45.	Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
46.	Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
47.	Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
48.	Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
49.	Combination Chemotherapy and Radiation Therapy With or Without Surgery In Treating Patients With Stage II or Stage III Bladder Cancer
50.	High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
51.	Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
52.	Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
53.	Biological Therapy in Treating Patients With Advanced Acute or Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
54.	Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
55.	Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Recurrent Myeloid Leukemias After Undergoing Allogeneic Stem Cell Transplantation
56.	PEG-Interferon alfa-2b and Thalidomide in Treating Patients With Recurrent High-Grade Gliomas
57.	Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
58.	FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer
59.	Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
60.	Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
61.	Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
62.	Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
63.	Monoclonal Antibody Therapy in Treating Patients with Refractory Lymphoma
64.	Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
65.	Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
66.	Vaccine Therapy Before and After Dose-Intensive Induction Chemotherapy Plus Immune-Depleting Chemotherapy in Treating Patients With Metastatic Breast Cancer
67.	Combination Chemotherapy and Thalidomide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
68.	Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
69.	Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
70.	Buspirone in Reducing Shortness of Breath in Patients With Cancer
71.	Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
72.	Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia
73.	Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
74.	Suramin and Paclitaxel in Treating Women With Stage IIIB or Stage IV Breast Cancer
75.	Study of Decision Making in Patients Participating in Phase I Clinical Trials
76.	Genetic Study of Cancer Risk and Gene Identification in Patients and Families With Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
77.	Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
78.	Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
79.	Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
80.	Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
81.	Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
82.	Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
83.	Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
84.	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
85.	Combination Chemotherapy in Treating Women With Stage I Breast Cancer
86.	Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
87.	Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
88.	Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
89.	Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
90.	Genetic Study of Familial Factors in Patients With Colon Cancer
91.	Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer
92.	Combination Chemotherapy Plus Erlotinib in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
93.	Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
94.	Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
95.	Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
96.	Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
97.	Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
98.	Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
99.	Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases from Colorectal Cancer
100.	Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides
101.	Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
102.	Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
103.	Surgery Followed By Chemotherapy With or Without Intraperitoneal Chemotherapy in Treating Patients With Peritoneal Carcinomatosis From Gastrointestinal Cancer
104.	Genetic Study of Cancer Risk and Gene Identification in Patients With Inherited Bone Marrow Disorders and Their Families
105.	Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
106.	Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
107.	Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer
108.	Reduced-Intensity Regimen Before Allogeneic Bone Marrow Transplantation in Treating Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
109.	Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
110.	BMS-247550 in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
111.	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
112.	Bevacizumab in Treating Patients With Kaposi's Sarcoma
113.	Zoledronate in Preventing Bone Loss Caused By Long-Term Androgen Deprivation Therapy in Patients With Stage III or Stage IV Prostate Cancer
114.	Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
115.	Flavopiridol, Fludarabine, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
116.	Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
117.	Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
118.	Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
119.	Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
120.	Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
121.	Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
122.	Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
123.	Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
124.	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
125.	Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
126.	Epirubicin and Thalidomide in Treating Patients With Liver Cancer
127.	Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
128.	Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
129.	Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
130.	Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
131.	Morinda Citrifolia in Treating Patients With Advanced Cancer
132.	Acupuncture in Improving Quality of LIfe in Patients With Metastatic Colorectal Cancer
133.	Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
134.	Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
135.	High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
136.	Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
137.	Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
138.	Monoclonal Antibody Therapy After Allogeneic Stem Cell Transplantation in Treating Patients With Persistent or Progressive Cancer
139.	Low-Dose Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Refractory Chronic Lymphocytic Leukemia
140.	Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
141.	Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
142.	Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach (Group Two Closed to Accrual as of 9/19/2006)
143.	Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
144.	Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
145.	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
146.	Interferon alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
147.	Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
148.	Interleukin-7 in Treating Patients With Refractory Solid Tumors
149.	FR901228 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
150.	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
151.	Diagnostic and Genetic Study to Identify Pancreatic Lesions in Patients With Von Hippel-Lindau Syndrome
152.	Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
153.	Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
154.	Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
155.	Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
156.	Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
157.	Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
158.	Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
159.	Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
160.	Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
161.	Collecting and Counting the Number of Endothelial Cells in the Circulating Blood of Patients with Cancer, Patients Having Surgery, and Healthy Volunteers
162.	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
163.	Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
164.	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
165.	Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
166.	Monoclonal Antibody and Sargramostim in Treating Patients With Metastatic Prostate Cancer
167.	Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
168.	Alemtuzumab in Treating Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma
169.	Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
170.	Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
171.	Fruit and Vegetable Extracts in Treating Patients With Stage I, Stage II, Stage III, Stage IVA, or Stage IVB Head and Neck Cancer
172.	High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
173.	Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
174.	Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
175.	Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
176.	Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
177.	Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
178.	Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
179.	Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
180.	Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
181.	Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
182.	Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
183.	Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
184.	Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin
185.	Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
186.	Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
187.	Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
188.	Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
189.	Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer
190.	Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
191.	Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
192.	Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
193.	Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
194.	Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
195.	Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
196.	Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
197.	Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
198.	Collecting and Storing Tissue Samples Taken From Patients With Endometrial Cancer During Surgery to Determine the Stage of the Cancer
199.	Vaccine Therapy in Treating Patients With Malignant Glioma
200.	Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
201.	Chemotherapy, Interferon alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
202.	Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
203.	Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
204.	Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
205.	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
206.	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
207.	Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
208.	Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
209.	Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia
210.	J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma
211.	Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance
212.	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
213.	Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
214.	Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
215.	Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
216.	Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer
217.	Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
218.	Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
219.	Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
220.	Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer
221.	Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
222.	Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
223.	Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
224.	Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
225.	Breast Duct Lavage, Breast Duct Endoscopy, and Gene Expression Profiling in Women With Breast Cancer Compared With Healthy Women Who Are and Are Not at High Risk for Breast Cancer
226.	Imatinib Mesylate or Dasatinib in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
227.	Proton Nuclear Magnetic Resonance Spectroscopic Imaging Compared With Fludeoxyglucose F 18 Positron Emission Tomography Scanning in Determining Biologic or Metabolic Tumor Activity in Young Patients With Brain Tumors
228.	GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
229.	Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
230.	Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
231.	Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
232.	Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
233.	Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
234.	CCI-779 in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
235.	Tariquidar and Docetaxel in Treating Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Kidney Cancer
236.	Neoadjuvant Capecitabine and Radiation Therapy With or Without TNFerade Followed By Surgical Resection in Treating Patients With Stage II, Stage III, or Locally Recurrent Rectal Cancer
237.	Alemtuzumab Combined With Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisone in Treating Patients Who Have Not Received Chemotherapy For T-Cell or NK-Cell Lymphoma
238.	Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
239.	Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
240.	Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma
241.	Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
242.	Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma
243.	Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
244.	Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
245.	Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
246.	Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
247.	Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
248.	Gemcitabine, Carboplatin, and Dexamethasone With or Without Rituximab in Treating Patients With Relapsed or Primary Refractory Lymphoma
249.	Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
250.	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
251.	Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
252.	Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide Plus Surgery in Treating Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer
253.	Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
254.	BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
255.	Infliximab in Treating Patients With Myelodysplastic Syndrome
256.	Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides
257.	Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
258.	Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma
259.	Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
260.	Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
261.	Induction Therapy Using Cisplatin, Etoposide, and Radiation Therapy Followed By Consolidation Therapy Using Gemcitabine With or Without Docetaxel in Treating Patients With Unresectable Stage IIIB Non-Small Cell Lung Cancer
262.	BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors
263.	Allogeneic Peripheral Stem Cell Transplant After Antithymocyte Globulin, High-Dose Melphalan, and Fludarabine in Treating Women With Metastatic Adenocarcinoma of the Breast
264.	Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
265.	Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
266.	Siplizumab in Treating Patients With Lymphoproliferative Disorder
267.	Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Sodium Thiosulfate in Treating Patients With High-Grade Glioma
268.	Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
269.	Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
270.	3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
271.	Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
272.	Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis
273.	Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
274.	Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
275.	Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
276.	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With N